Invesco Ltd. Reduces Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Invesco Ltd. trimmed its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 93.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,944 shares of the company's stock after selling 738,635 shares during the quarter. Invesco Ltd. owned 0.05% of Aquestive Therapeutics worth $171,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. New York State Common Retirement Fund boosted its holdings in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after buying an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aquestive Therapeutics in the fourth quarter valued at $44,000. PKS Advisory Services LLC purchased a new position in Aquestive Therapeutics during the 4th quarter valued at about $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at about $69,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Aquestive Therapeutics during the 4th quarter valued at $115,000. 32.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on AQST shares. Lake Street Capital decreased their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.01 during mid-day trading on Friday, reaching $2.75. 300,419 shares of the company traded hands, compared to its average volume of 1,453,531. Aquestive Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $5.80. The firm has a market cap of $273.13 million, a PE ratio of -6.11 and a beta of 2.02. The company's 50 day moving average price is $2.78 and its 200-day moving average price is $3.49.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. On average, research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.